— Know what they know.
Not Investment Advice

PACB NASDAQ

Pacific Biosciences of California, Inc.
1W: +25.0% 1M: +43.3% 3M: +75.0% YTD: +33.1% 1Y: +21.3% 3Y: -66.8% 5Y: -90.3%
$2.45
+0.20 (+8.89%)
Pre-Market: $2.44 (-0.02, -0.61%)
Weekly Expected Move ±21.8%
$1 $2 $2 $3 $3
NASDAQ · Healthcare · Medical - Devices · Tech Score Buy · Power 62 · $761.5M mcap · 304M float · 3.22% daily turnover · Short 54% of daily vol
Credit Risk of going bust: higher than 91% of companies Debt: 48.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.29 (down 88%), Pacific Biosciences of California, Inc. would be worth roughly what it owes.
Total debt $706.1M against a stock market value of $761.5M.
Distance to default 1.52 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $322.2M (short-term plus half of long-term), stock volatility 92.2%; Altman Z -4.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$784M -37.8% ▼
5Y CAGR: +13.6%
Total Liabilities
$779M +3.3% ▲
5Y CAGR: +58.2%
Shareholders Equity
$5M -98.9% ▼
5Y CAGR: -56.3%
Cash & Investments
$280M -28.3% ▼
5Y CAGR: -2.6%
Total Debt
$759M +12.9% ▲
5Y CAGR: +78.4%
Net Debt
$696M +12.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$461M$325M$180M$55M$64M
Short-Term Investments$584M$447M$452M$335M$216M
Cash & ST Investments$1.0B$772M$631M$390M$280M
Net Receivables$24M$19M$37M$28M$35M
Inventory$25M$50M$57M$59M$49M
Other Current Assets$500K$300K$17M$19M$11M
Total Current Assets$1.1B$852M$742M$496M$375M
Property, Plant & Equip.$79M$81M$69M$47M$66M
Goodwill & Intangibles$821M$820M$919M$707M$333M
Long-Term Investments$0$0$0$0$2M
Other Non-Current Assets$6M$13M$16M$11M$9M
Total Non-Current Assets$906M$915M$1.0B$765M$409M
Total Assets$2.0B$1.8B$1.7B$1.3B$784M
— Liabilities —
Accounts Payable$11M$12M$15M$17M$21M
Short-Term Debt$2M$2M$490K$0$448K
Deferred Revenue$11M$30M$16M$14M$0
Other Current Liabilities$4M$175M$8M$3M$33M
Total Current Liabilities$72M$263M$95M$66M$54M
Long-Term Debt$896M$897M$892M$647M$702M
Other Non-Current Liab.$198M$1M$20M$19M-$55M
Total Non-Current Liabilities$1.1B$941M$950M$688M$724M
Total Liabilities$1.2B$1.2B$1.0B$754M$779M
— Equity —
Common Stock$221K$227K$268K$294K$302K
Retained Earnings-$1.2B-$1.5B-$1.8B-$2.1B-$2.7B
Accumulated OCI-$1M-$5M$219K$422K$457K
Total Stockholders Equity$791M$563M$701M$507M$5M
Total Liabilities & Equity$2.0B$1.8B$1.7B$1.3B$784M
— Key Metrics —
Total Debt$955M$948M$934M$672M$759M
Net Debt$495M$623M$754M$617M$696M
Total Investments$584M$447M$452M$335M$217M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms